权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of Next-generation Pharmacotherapy for Opioid Use Disorders

开发治疗阿片类药物使用障碍的下一代药物疗法

基本信息

批准号：
10680546
负责人：
Nurulain T Zaveri
金额：
$ 218.35万
依托单位：
ASTRAEA THERAPEUTICS, LLC
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-01-01 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10680546
关键词：
Address Agonist Alcohols Analgesics Analytical Chemistry Attenuated Biological Assay Buprenorphine Chemicals Chronic Clinical Clinical Research Cocaine Cyclic GMP Data Dependence Development Documentation Dose Drug usage Evaluation Formulation Goals Heroin In Vitro Intake Intellectual Property Laboratories Lead Ligands Lymphoma Macaca mulatta Methadone Micronucleus Tests Monkeys Morphine Mus ORL1 receptor Opioid Opioid Antagonist Opioid Receptor Opioid agonist Oral Overdose Oxycodone Pain Peptide Receptor Pharmaceutical Preparations Pharmacology Pharmacotherapy Phase Phase I Clinical Trials Physical Dependence Preparation Process Property Recovery Relapse Rewards Risk Rodent Safety Secure Self Administration Series Telemetry Toxic effect Toxicokinetics Toxicology Training Validation Ventilatory Depression Withdrawal Withdrawal Symptom abuse liability addiction chronic pain craving design drug candidate illicit opioid in vivo kappa opioid receptors lead candidate lead optimization medication for opioid use disorder meetings methadone clinic/center method development mu opioid receptors next generation nociceptin nonhuman primate novel novel strategies opioid epidemic opioid use disorder pre-clinical preclinical development prescription opioid prescription opioid addiction response reward circuitry safety study scaffold scale up small molecule

项目摘要

ABSTRACT: This application in response to RFA-DA-19-002 proposes a phased plan that will fast track the IND development of a next-generation medication for opioid use disorders (OUD). The small-molecule compounds proposed for development are targeted to the nociceptin opioid receptor (NOP) and have shown promising efficacy in reducing oxycodone intake in nonhuman primates (rhesus monkeys) trained to self-administer oxycodone with efficacies similar to that of buprenorphine. But unlike buprenorphine, the NOP-targeted agonist lead compounds show no reinforcing effects by themselves, in monkeys. Also unlike buprenorphine and methadone, currently used for treating OUDs, NOP-targeted lead compounds do not produce physical dependence, tolerance, or respiratory depression, upon repeated administration. For the non-medical prescription opioid addiction, methadone and buprenorphine, both approved for illicit opioid (heroin) addiction treatment, are used. However, methadone, a mu opioid receptor (MOP) full agonist has significant abuse liability and causes withdrawal after chronic use, reliance on methadone clinics, and risk of drug overdose- induced respiratory depression. Buprenorphine (Bup), a MOP partial agonist and kappa opioid receptor (KOP) antagonist, produces limited respiratory depression; however, clinical studies indicate that it is less effective than methadone in reducing drug use, craving and relapse. Agonists targeted to the nociceptin/orphanin FQ peptide (NOP) receptor, the fourth opioid receptor subtype, modulate the pharmacology of MOP agonists and opioids, particularly in pain and reward circuitries. Our preliminary data shows that small-molecule NOP agonists reduce morphine-induced reward in rodents and this is further confirmed in our preliminary data in nonhuman primates, demonstrating promising anti-rewarding properties of a NOP/MOP partial agonist in decreasing oxycodone self-administration without producing dependence or respiratory depression. Together our data thus far suggests that the NOP agonists are a promising new approach to treat illicit and prescription opioid use disorders and may offer an alternative to buprenorphine use. In the UG3 phase of this project, we propose to conduct non-GLP ADME-tox and efficacy confirmation, and additional lead optimization if warranted, with the goal/milestone being the nomination of a `IND candidate' and backup candidates, for IND-enabling studies and an IND filing (in the UH3phase).

文摘: